AtriCure Inc
$ 29.40
2.58%
14 Apr - close price
- Market Cap 1,488,663,000 USD
- Current Price $ 29.40
- High / Low $ 29.76 / 28.88
- Stock P/E N/A
- Book Value 9.88
- EPS -0.24
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.01 %
- ROE -0.02 %
- 52 Week High 43.18
- 52 Week Low 27.26
About
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. The company is headquartered in Mason, Ohio.
Analyst Target Price
$47.88
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-10-29 | 2025-07-28 | 2025-04-29 | 2025-02-13 | 2024-10-29 | 2024-07-30 | 2024-05-01 | 2024-02-15 | 2023-11-01 | 2023-07-25 | 2023-05-02 |
| Reported EPS | 0.06 | -0.01 | -0.02 | -0.14 | -0.08 | -0.17 | -0.17 | -0.28 | -0.21 | -0.2 | -0.11 | -0.23 |
| Estimated EPS | -0.0991 | -0.11 | -0.167 | -0.2234 | -0.1488 | -0.19 | -0.17 | -0.23 | -0.23 | -0.31 | -0.3 | -0.34 |
| Surprise | 0.1591 | 0.1 | 0.147 | 0.0834 | 0.0688 | 0.02 | 0 | -0.05 | 0.02 | 0.11 | 0.19 | 0.11 |
| Surprise Percentage | 160.5449% | 90.9091% | 88.024% | 37.3321% | 46.2366% | 10.5263% | 0% | -21.7391% | 8.6957% | 35.4839% | 63.3333% | 32.3529% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.07 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ATRC
2026-04-14 12:09:50
AtriCure, Inc. (Nasdaq: ATRC) announced it will release its first-quarter 2026 financial results on Tuesday, May 5, 2026. The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss the results. AtriCure specializes in surgical treatments and therapies for atrial fibrillation, left atrial appendage management, and post-operative pain management.
2026-04-11 05:08:49
Representative Gilbert Ray Cisneros, Jr. (D-CA) recently purchased shares in AtriCure, Inc. (NASDAQ:ATRC), a medical device company specializing in atrial fibrillation treatments. The transaction, valued between $1,001 and $15,000, occurred on March 3rd and was publicly disclosed on April 7th. This acquisition adds to his existing holdings in the company, whose product portfolio includes surgical ablation and cryoablation systems.
2026-04-10 01:10:43
AtriCure Inc.'s stock recently hit a 52-week low of $27.30, experiencing a nearly 29% decline year-to-date and a 13.08% drop over the past year, reflecting broader market volatility and industry-specific pressures in the medical device sector. Despite this downturn, analysts remain optimistic with price targets up to $54 and InvestingPro data indicating the stock is undervalued with a "GOOD" financial health score. The company reported strong Q4 2025 revenue of $140.5 million, surpassing analyst expectations, and maintained its 2026 revenue and adjusted EBITDA guidance, though analyst ratings have shown varied adjustments to price targets.
2026-04-09 14:09:29
AtriCure Inc.'s stock has reached a 52-week low of $27.30, reflecting significant market challenges and a nearly 29% year-to-date decline. Despite the downturn and broader market volatility, analysts remain optimistic with price targets suggesting potential upside, and InvestingPro data indicates the stock is undervalued with "GOOD" financial health. The company recently reported strong Q4 2025 revenues that exceeded expectations and maintained its 2026 guidance, though analyst ratings have shown mixed reactions.
2026-04-08 13:36:00
This article provides an in-depth analysis of Atricure Inc. (NASDAQ: ATRC) based on AI-generated signals. It highlights "divergent sentiment readings" and "elevated downside risk," offering three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, complete with entry, target, and stop-loss zones. The analysis also includes a multi-timeframe signal breakdown for near-term, mid-term, and long-term horizons, advising on support and resistance levels.
2026-04-06 15:41:25
AtriCure Inc. (NASDAQ: ATRC) will hold its 2026 annual meeting virtually on May 18, 2026, where stockholders will vote on several proposals, including expanding its equity compensation plans. The company seeks to add 1.5 million shares to its 2023 Stock Incentive Plan and 750,000 shares to its 2018 Employee Stock Purchase Plan, totaling 2.25 million additional shares. Other agenda items include the election of nine directors, ratification of Deloitte & Touche LLP as the independent auditor for 2026, and an advisory "say-on-pay" vote for named executive officer compensation.
